IBRO Neuroscience Reports
August 1, 2026
Remko Van Lutterveld, Thomas Cahaly, Lukas van Herk et al.
Advanced meditation includes meditative endpoints that are outcomes of meditation practice and occur with time and mastery of meditation. The “cessation” event (c.f. nirodha in Theravada Buddhism) is a meditative endpoint characterized by a loss of consciousness followed by a sense of mental reset and deep clarity. In general, organization of brain activity exists along a “criticality”...
IBRO Neuroscience Reports
July 26, 2026
Jingwen Yang, Ting Huang, Meng Wang et al.
Background Deeper understanding of ketamine’s mechanism of action would contribute to the discovery of novel therapeutic targets with fast-onset actions. To gain insight on the mechanism underlying the antidepressant-like effects of ketamine, we focused on perineuronal nets (PNNs), an extracellular matrix structure that surrounds fast-spiking parvalbumin-positive interneurons and regulates...
IBRO Neuroscience Reports
December 1, 2025
W Tanner Creel, Richard E Hartman
6 citations
A fundamental challenge in clinical neuropsychology is the objective assessment of emotion regulation and resilience. Current reliance on self-report is hampered by bias, creating a critical need for brain-based biomarkers that can capture the dynamics of emotional functioning. This review advances EEG entropy modulation as a theoretically appealing and emerging candidate. Converging research...
IBRO Neuroscience Reports
December 1, 2024
Ntombifuthi P Ngubane, Musa V Mabandla, Brenda Z De Gama
3 citations
Salix mucronata is one of the herbal plants offered by the traditional health practitioners in KwaZulu-Natal, South Africa for the treatment of schizophrenia. This study aimed to investigate the effects of repeated administration of ketamine on social interaction, novelty and motivation in adult, male Sprague Dawley rats. It also aimed to investigate the potential of risperidone and the herbal...
IBRO Neuroscience Reports
December 1, 2024
Gabriela N Vaz, Flávia C Turcato, Isabel A V Lima et al.
About one-third of major depressive disorder (MDD) patients demonstrate unresponsiveness to classic antidepressants, and even the clinical efficacy of fast-acting drugs such as ketamine varies significantly among patients with treatment-resistant depression. Nevertheless, the lack of suitable animal models that mimic a possible ketamine-resistant phenotype challenges the understanding of...
IBRO Neuroscience Reports
January 3, 2024
Benneth Ben-Azu, Olusegun G Adebayo, Aliance R Fokoua et al.
A decrease in the levels of antioxidant arsenals exacerbate generation of reactive oxygen/nitrogen species, leading to neurochemical dysfunction, with significant impact on the pathogenesis of psychotic disorders such as schizophrenia. This study examined the preventive and reversal effects of diosgenin, a phyto-steroidal saponin with antioxidant functions in mice treated with ketamine which...
IBRO Neuroscience Reports
November 6, 2023
Tomáš Páleníček, Tereza Klučková, Marek Nikolič et al.
INTRODUCTION: The mechanisms by which the psychedelic drug psilocybin, a novel rapid-acting antidepressant, improves depressive symptoms are still unclear. One candidate mechanism is the impact of the phenomenology of the psychedelic experience, with positive phenomenology hypothesised to be associated with positive long-term outcomes and fearful phenomenology hypothesised to be associated with...
IBRO Neuroscience Reports
October 1, 2023
Mariana Pazos, Ignacio Carrera, Giselle Prunell
1 citation
Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for a variety of medicinal, spiritual, and cultural purposes. It is prepared by decoction of the vine Banisteriopsis caapi, source of β-carboline alkaloids, and, Psychotria viridis containing the classic psychedelic N,N-dimethyltryptamine (DMT). As part of the “renaissance of...
IBRO Neuroscience Reports
October 1, 2023
Aneta Petrušková, Eva‐maria Weiss, Debarpan Guhathakurta et al.
Serotonergic psychedelics (SP) such as psilocybin, LSD or DMT pose significant potential for development of new strategies in treating neuropsychiatric disorders including major depression disorder, post-traumatic stress disorder and addiction. To bring these substances to clinical application, however, better understanding of the mechanisms behind their effects on many levels, including...
IBRO Neuroscience Reports
October 1, 2023
Čestmír Vejmola, Kateřina Syrová, Klára Šíchová et al.
GABAB receptors are the metabotropic GABA neurotransmitter receptors in the central nervous system constituting a fundamental part of the inhibitory modulation mechanism.These receptors are heterodimers composed of GABAB1 and GABAB2 which function is modulated by the potassium channel tetramerization domain proteins (KCTD) from clade F (KCTD16; KCTD12 and KCTD8).In our experiments we explored...
IBRO Neuroscience Reports
May 1, 2022
Anh An, H. Hoang, Long Trang et al.
Financial constraints usually hinder students, especially those in low-middle income countries (LMICs), from seeking mental health interventions. Hence, it is necessary to identify effective, affordable and sustainable counter-stress measures for college students in the LMICs context. This study examines the sustained effects of mindfulness practice on the psychological outcomes and brain...